Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells - PubMed (original) (raw)
. 1998 Dec 15;161(12):6977-84.
Affiliations
- PMID: 9862733
Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells
A I Chapoval et al. J Immunol. 1998.
Abstract
Previous studies have demonstrated that IL-15 administration after cyclophosphamide (CY) injection of C57BL/6J mice bearing the i.m. 76-9 rhabdomyosarcoma resulted in a significant prolongation of life. In the present study, we investigated the immune response against the 76-9 experimental lung metastases after CY + IL-15 therapy. Administration of CY + IL-15, but not IL-15 alone, induced prolongation of life and cures in 32% of mice bearing established experimental pulmonary metastases of 76-9 tumor. The CY + IL-15 therapy resulted in increased levels of NK1.1+/LGL-1+ cells, and CD8+/CD44+ T cells in PBL. In vitro cytotoxic assay of PBL indicated the induction of lymphokine-activated killer cell activity, but no evident tumor-specific class I-restricted lytic activity. Survival studies showed that the presence of NK and T lymphocytes is necessary for successful CY + IL-15 therapy. Experiments using knockout mice implied that either alphabeta or gammadelta T cells were required for an antitumor effect induced by CY + IL-15 therapy. However, mice lacking in both alphabeta and gammadelta T cells failed to respond to combination therapy. Cured B6 and alphabeta or gammadelta T cell-deficient mice were immune to rechallenge with 76-9, but not B16LM tumor. B cell-deficient mice showed a significant improvement in the survival rate both after CY and combination CY + IL-15 therapy compared with normal B6 mice. Overall, the data suggest that the interaction of NK cells with tumor-specific alphabeta or gammadelta T lymphocytes is necessary for successful therapy, while B cells appear to suppress the antitumor effects of CY + IL-15 therapy.
Similar articles
- IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R, Fuller JA, Christianson G, Krupke DM, Troutt AB. Evans R, et al. Cell Immunol. 1997 Jul 10;179(1):66-73. doi: 10.1006/cimm.1997.1132. Cell Immunol. 1997. PMID: 9259773 - Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP. Hillman GG, et al. Clin Cancer Res. 1997 Oct;3(10):1799-806. Clin Cancer Res. 1997. PMID: 9815566 - Cytotoxic cells in immunodeficient athymic mice.
Budzynski W, Radzikowski C. Budzynski W, et al. Immunopharmacol Immunotoxicol. 1994 Aug;16(3):319-46. doi: 10.3109/08923979409007097. Immunopharmacol Immunotoxicol. 1994. PMID: 7528237 Review. - Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H, Lotze MT. Tahara H, et al. Gene Ther. 1995 Mar;2(2):96-106. Gene Ther. 1995. PMID: 7719935 Review.
Cited by
- Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes.
Katakai T. Katakai T. Front Oncol. 2023 Jan 24;13:1088129. doi: 10.3389/fonc.2023.1088129. eCollection 2023. Front Oncol. 2023. PMID: 36761946 Free PMC article. Review. - Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V, Stellas D, Karaliota S, Nagy BA, Valentin A, Bergamaschi C, Dimas K, Pavlakis GN. Stravokefalou V, et al. Front Immunol. 2023 Jan 13;13:1014802. doi: 10.3389/fimmu.2022.1014802. eCollection 2022. Front Immunol. 2023. PMID: 36713398 Free PMC article. - Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer.
Shanmugam G, Das S, Paul S, Rakshit S, Sarkar K. Shanmugam G, et al. Med Oncol. 2022 Sep 29;39(12):237. doi: 10.1007/s12032-022-01841-6. Med Oncol. 2022. PMID: 36175603 Review. - Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Tousif S, Wang Y, Jackson J, Hough KP, Strenkowski JG, Athar M, Thannickal VJ, McCusker RH, Ponnazhagan S, Deshane JS. Tousif S, et al. Front Immunol. 2021 Nov 19;12:747780. doi: 10.3389/fimmu.2021.747780. eCollection 2021. Front Immunol. 2021. PMID: 34867973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous